+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Genmab AS - logo

Genmab is a leading biotechnology company that focuses on developing innovative antibody products. Arzerra is the company’s first marketed antibody and is approved to treat chronic lymphocytic leukemia (CLL) patients in all major markets. Another product, Darzalex, has been approved in the United States for the treatment of patients with multiple myeloma. Genmab was founded in Copenhagen, Denmark in 1999 and employs around 200 people.

From
US Bispecific Antibodies Market & Clinical Pipeline Insight 2028 - Product Thumbnail Image

US Bispecific Antibodies Market & Clinical Pipeline Insight 2028

  • Drug Pipelines
  • August 2023
  • 580 Pages
  • United States
From
China Bispecific Antibodies Market and Clinical Pipeline Insight 2028 - Product Thumbnail Image

China Bispecific Antibodies Market and Clinical Pipeline Insight 2028

  • Drug Pipelines
  • August 2023
  • 400 Pages
  • China
From
Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2020 - Product Thumbnail Image

Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2020

  • Drug Pipelines
  • July 2020
  • 419 Pages
  • Global
From
Global Cancer Monoclonal Antibodies Market & Clinical Trial Insight 2024 - Product Thumbnail Image

Global Cancer Monoclonal Antibodies Market & Clinical Trial Insight 2024

  • Clinical Trials
  • November 2018
  • 1100 Pages
  • Global
From
From
From
From
From
From
Global Anti-CD20 Monoclonal Antibodies (mABs) Market 2024-2028 - Product Thumbnail Image

Global Anti-CD20 Monoclonal Antibodies (mABs) Market 2024-2028

  • Report
  • October 2023
  • 161 Pages
  • Global
From
Loading Indicator